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Abstract
Heterogeneity of embryological origins is a hallmark of vascular smooth muscle cells (SMCs),
which may influence vascular disease development. Differentiation of human pluripotent stem
cells (hPSCs) into developmental origin-specific SMC subtypes remains elusive. In this study, we
have established a chemically defined protocol where hPSCs were initially induced to form
neuroectoderm, lateral plate mesoderm or paraxial mesoderm. These intermediate populations
were further differentiated towards SMCs (>80% MYH11+ and ACTA2+) which displayed
contractile ability in response to vasoconstrictors and invested perivascular regions in vivo.
Derived SMC subtypes recapitulated the unique proliferative and secretory responses to cytokines
previously documented in studies using aortic SMCs of distinct origins. Importantly, this system
predicted increased extracellular matrix degradation by SMCs derived from lateral plate
mesoderm, which was confirmed using rat aortic SMCs from corresponding origins. Collectively,
this work will have broad applications in modeling origin-dependent disease susceptibility and in
bio-engineered vascular grafts for regenerative medicine.
Introduction
Vascular SMCs and pericytes comprise the walls of larger vessels and capillary beds
respectively1. Interestingly, lineage tracking studies have shown that vascular SMCs in
different vessels have distinct embryological origins2. For example, the basal aortic root is
derived from secondary heart field3 while the ascending aorta and the arch are neural crest
derived4. Descending aortic SMCs originate from paraxial/somitic mesoderm5. Coronary
SMCs arise from the pro-epicardial organ which is of lateral plate mesodermal origin6.
Although information on the embryological origins of pericytes is relatively lacking, there is
considerable phenotypic overlap between these cells and SMCs. Consistent with the
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phenotypic similarities, it appears that SMCs and pericytes in the same vascular region share
common origins7-10.
The diversity of SMC origins may in part contribute to the site-specific localization of
vascular diseases including regional susceptibility to atherosclerosis11, 12, vascular
calcification13 and aortic aneurysm distribution14. Notably, aortic dissections occur
preferentially at the interfaces where SMCs of distinct embryological origins meet. Together
these findings suggest that intrinsic lineage-derived differences between SMCs may play a
role in the spatiotemporal pattern of vascular diseases. Therefore, a model system to
investigate how SMC embryological origins influence development of vascular diseases
would be valuable.
Currently, SMC derivation from human embryonic or induced pluripotent stem cells (hESCs
or iPSCs), collectively known as hPSCs usually requires serum and does not encompass the
concept of using a lineage-specific approach15. We report a chemically defined method for
generating origin-specific SMCs from hPSCs via three intermediate lineages –
neuroectoderm, lateral plate mesoderm and paraxial mesoderm. We used our in vitro system
to predict the responses of different SMC subtypes to interleukin-1β (IL-1β), an
inflammatory mediator, and validated the results using rat aortic SMCs of distinct origins.
Our finding reveals that origin-specific SMCs exhibit differential activation of matrix
metalloproteinase 9 (MMP9) and tissue inhibitor of metalloproteinase 1 (TIMP1). Hence,
our SMC subtypes could potentially be used to study origin-dependent disease susceptibility
and also serve as a source of therapeutic cells for vascular regenerative medicine.
Results
Mesoderm subtypes can be specified by manipulation of BMP and PI3K pathways
The H9 hESC line, which is chromosomally normal (Supplementary Fig. 1a), was used to
study the specification of the various lineages from which SMCs arise. For neuroectoderm
differentiation, we adopted our previously published protocol16, using fibroblast growth
factor 2, (FGF2, 12 ng/ml) and the activin/nodal inhibitor, SB431542 (10 μM). During the
induction of neuroectoderm in hESCs, we observed a marked decrease in expression of the
pluripotency marker, NANOG, within 2 days (Supplementary Fig. 1b). The expression of
neuroectoderm markers (GBX2, OLIG3 and SOX1) increased over time and peaked
between day 6 and day 8, as documented before16. Extensive immunostaining for
neuroectoderm markers (PAX6 and NESTIN) was observed in both hESCs and human
iPSCs after 7 days of FGF2 and SB431542 treatment. High efficiency of neuroectoderm
induction was observed with over 90% of the cells double positive for PAX6 and NESTIN
(Supplementary Fig. 1c). For mesoderm subtype differentiation, we utilized our previously
described 36-hour early mesoderm differentiation protocol17. A combination of FGF2 (20
ng/ml), phosphoinositide 3-kinase (PI3K) inhibitor (LY294002, 10 μM) and bone
morphogenetic protein 4 (BMP4, 10 ng/ml), herein referred to as FLyB, was used (Fig.
1ai). Subsequent mesoderm subtype specification was further investigated.
During embryogenesis, specification of lateral plate mesoderm and paraxial mesoderm
follows a posterior-anterior BMP gradient along the primitive streak18 (Fig 1aii). We
hypothesized that by varying the BMP4 concentration according to these developmental
principles, we would obtain the relevant mesoderm subtypes from hPSCs. Studies have
suggested that BMP signaling is a key driver of mesoderm19-22 and BMP4 also cooperates
with ActivinA to induce differentiation of mesendoderm, the precursor of mesoderm and
endoderm16. We examined the roles of BMP4 and ActivinA in mesoderm subtype
specification from the early mesoderm stage while keeping FGF2 (20 ng/ml) and LY294002
(10 μM) constant. In the presence of ActivinA (10 ng/ml, black bars), BMP4 promoted the
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expression of the lateral plate marker, KDR, in a dose-dependent way (from 0 ng/ml to 100
ng/ml, i.e. B0 to B100, respectively) (Fig. 1b). Endogenous BMP signaling (B0 condition)
was insufficient to promote KDR expression since Noggin (Nog), a BMP antagonist,
produced the same effect as B0. Absence of ActivinA (white bars) did not affect the
development of lateral plate mesoderm since KDR was expressed as long as BMP4 was
added. In contrast, absence of ActivinA promoted the expression of the paraxial marker,
MEOX1, in the absence of BMP (Nog and B0 conditions). ActivinA was therefore
dispensable for mesoderm formation while high concentration of BMP4 enhanced lateral
plate mesoderm specification but inhibited paraxial mesoderm specification.
We then evaluated the effect of LY294002 (Ly, 10 μM) on mesoderm subtype specification.
Ly has been shown to facilitate differentiation of hESCs23. Interestingly we found that, in
the presence of FGF2 (F, 20 ng/ml) alone, Ly (10 μM, black bars) significantly promoted
the expression of a panel of paraxial markers, MEOX1 (P = 0.0051), TBX6 (P = 0.0027),
TCF15 (P = 0.0001) and PAX1 (P = 0.0087), versus no Ly (white bars) (Fig. 1c). Again, the
presence of BMP4 (B50, 50 ng/ml) inhibited the expression of all paraxial markers and
promoted the expression of lateral plate markers. On the other hand, Ly significantly
downregulated the lateral plate markers, LMO2 (P = 0.00024 in F, P = 0.00002 in FB50),
PECAM1 (P = 0.0037 in F, P = 0.00167 in FB50), NKX2-5 (P = 0.0170 in F) and ISL1 (P =
0.0132 in F) compared to the no Ly condition. Hence, we established the optimal conditions
for lateral plate and paraxial mesoderm sub-specification to be FB50 (FGF2, 20 ng/ml +
BMP4, 50 ng.ml) and FLy (FGF2, 20 ng/ml + LY294002, 10 μM) respectively.
We next determined the time-scale of mesoderm subtype differentiation. NANOG
expression decreased markedly within 2 days of differentiation of hESCs (Fig. 1d).
Brachyury (T), a primitive streak and early mesoderm marker, emerged transiently and
peaked at 36 hours after FLyB treatment. Further specification demonstrated that FB50 (red
lines) increased the expression of lateral plate genes (MESP1, KDR, NKX2-5 and ISL1)
from as early as day 2 of differentiation and, peaking at days 4 to 5. In contrast, FLy (blue
lines) upregulated paraxial genes (TBX6, MEOX1, TCF15 and PAX1) only, with peak
expression between days 3 and 5. Flow cytometry confirmed that FB50 (white bars)
treatment significantly promoted lateral plate mesoderm development, with 82.4 ± 5.1%
KDR-expressing cells at day 5 compared to 2.12 ± 0.21% under the FLy (black bars)
treatment (P = 0.0004) (Supplementary Fig. 1d). Meanwhile, FLy treatment resulted in 67.5
± 7.3% TCF15-expressing cells at day 5, versus 1.25 ± 0.05% using FB50 (P = 0.0008),
indicative of paraxial mesoderm formation primarily. Representative flow cytometric plots
are shown in Fig. 1e. Day 5 populations generated by either FB50 or FLy treatment also
stained positively for their respective mesoderm subtype markers by immunofluorescence
(Fig. 1f). We therefore identified day 5 as the time point when the relevant mesoderm
subtypes were optimally specified (Fig. 1d-f, Supplementary Fig. 1c). In summary, we
devised for the first time, a method to derive either paraxial or lateral plate mesoderm
subtypes from hESCs.
Vascular SMC subtypes are generated with high efficiency from three intermediate
lineages
During vessel development, platelet-derived growth factor BB (PDGF-BB) induces
differentiation of mesenchymal progenitors into vascular SMCs24. Upon investment of
SMCs to the newly formed blood vessels, transforming growth factor-beta 1 (TGF-β1)
promotes SMC maturation and regulates vessel remodeling24. We tested the effects of
PDGF-BB (10 ng/ml) and TGF-β1 (2 ng/ml), as well as two other SMC inducers, retinoic
acid (RA, 1 μM) and sphingosylphosphorylcholine (SPC, 5 μM), on our derived
intermediate populations, namely neuroectoderm (NE), lateral plate mesoderm (LM) and
paraxial mesoderm (PM). A combination of the two best inducers, PDGF-BB and TGF-β1
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[PT treatment (PDGF-BB, 10ng/ml + TGF-β1, 2ng/ml)], promoted the highest expression of
the SMC marker, MYH11, from all the intermediate populations (Supplementary Fig. 2a).
Combined protocols to derive origin-specific SMCs from hPSCs are outlined in Fig. 2a.
Henceforth, we will refer to the neuroectoderm-derived SMC, lateral plate mesoderm-
derived SMC and paraxial mesoderm–derived SMC as NE-SMC, LM-SMC and PM-SMC
respectively (Fig. 2a).
The expression of multiple SMC markers increased over time with PT treatment and peaked
between day 9 and day 12 with upregulation of early SMC markers (ACTA2, TAGLN,
CNN1) preceding the late markers (SMTN, MYH11) (Fig. 2b). The derived SMCs after 12
days of PT treatment demonstrated comparable gene expression levels to the positive
control, human aortic SMCs (ASMC) (Supplementary Fig. 2b). Flow cytometric analysis
correlated with the gene expression data documenting an increment in the percentage of
cells doubly positive for MYH11 and ACTA2 over this period (Supplementary Fig. 2c).
Twelve days of PT treatment culminated in over 80% MYH11+/ACTA2+ cells generated
from the three intermediate populations, comparable to ASMC. A small proportion of cells
in the intermediate populations (3-8%) and during early SMC differentiation (2-7%)
expressed the pericyte marker, CSPG4 (Supplementary Fig. 2d). Notably, there was little or
no co-expression of CSPG4 and MYH11 suggesting that differentiating cells could adopt
either a SMC or a pericyte-like phenotype. By day 12 of PT treatment, the pericyte-like
population diminished, suggesting that the differentiation conditions had selected for SMCs
(>86% MYH11+). Two isoforms of smoothelin, namely smoothelin-A and smoothelin-B,
have been reported to be specifically expressed in the visceral and vascular SMCs
respectively25. Our derived SMCs exhibited up to ten fold lower smoothelin-A expression
levels than human gut derived sample although smoothelin-B expression was comparable to
ASMC, suggesting that the differentiation conditions favored vascular SMC specification
(Supplementary Fig. 2e). This highly efficient process to derive origin-specific SMCs was
reproducible in two hESC lines (H1 and H9), and a wild-type iPSC line (Fig. 2c).
Since vascular SMCs arise more precisely from the neural crest, a descendant of
neuroectoderm, we investigated whether there was transient formation of neural crest during
neuroectoderm to SMC differentiation. Indeed, expression of BMP4 and BMP7, required for
neural crest differentiation26, increased following PT treatment, prior to the peak expression
of neural crest markers, SNAI1 and SNAI2 at day 3 (Supplementary Fig. 2f). The other
neural crest markers, PAX3 and SOX10, displayed higher expression during the first 2 days
of PT treatment as BMP expression levels increased. We reasoned that the spontaneous
formation of neural crest could be due to the endogenous production of BMP4 and BMP7.
Microarray analysis was performed to characterize the hPSC-derived SMCs. Differentiated
SMCs demonstrated a downregulation of pluripotency genes, accompanied by upregulation
of vascular SMC genes (Fig. 2d). Furthermore, genes relating to neuronal, cardiac/
endothelial/hematopoietic and skeletal muscle lineages, which are the other potential
derivatives of neuroectoderm, lateral plate mesoderm and paraxial mesoderm respectively,
were repressed. Immunocytochemistry showed extensive staining for SMC markers in the
derived SMCs and positive control, human ASMCs, but not in the negative control, human
umbilical vein endothelial cells (HUVECs) (Fig. 2e). Western blot also demonstrated the
presence of mature SMC proteins, MYH11 and SMTN, in our derived SMCs and ASMCs,
which were absent in HUVECs (Fig. 2f). Overall, these results suggest that by mimicking
embryonic development, we developed a robust process to directly differentiate hPSCs into
origin-specific SMCs using a series of growth factor manipulations in a chemically defined
medium.
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Origin-specific vascular SMCs are functional
Despite the divergent initial differentiation routes, microarray analysis revealed that the
three types of derived SMCs shared many genes (3,604) differentially upregulated compared
to hESC (FDR 0.1%) (Fig. 3a). Among the highly enriched functional classifications of the
3,604 genes, there were the classical SMC functionality categories such as blood vessel
morphogenesis, extracellular matrix (ECM) interaction and actin cytoskeleton organization
(see Fig. 3a, gene lists of highlighted groups found in Supplementary Table 1).
Alternatively, the significantly enriched functional classifications of the non-overlapping
gene subsets revealed inherent differences among SMC subtypes (Supplementary Fig. 3a).
For example in NE-SMC, there were categories related to myelination and synaptic
transmission, both of which are neuronal characteristics, supporting the common
neuroectoderm origin of NE-SMC and neurons. In particular, LM-SMC was highly enriched
in genes promoting cell migration and consistent with this enrichment, these cells also
displayed the greatest migration in a scratch assay (Supplementary Fig. 3b).
To assess SMC contractile potential, we initially performed immunostaining for vinculin
and phalloidin staining for actin filaments. Well developed focal adhesion complexes were
detected in all three SMC sub-types (Supplementary Fig. 3c). The cells were then preloaded
with a calcium-sensitive dye, Fluo-4. Carbachol (100 μM) stimulated an increase in Fluo-4
fluorescence intensity in the derived SMCs within 1 minute of treatment (red, blue and green
lines, Fig. 3bi), indicating increased intracellular calcium flux. After 2 minutes of treatment,
Fluo-4 intensity decreased, approaching original basal levels by 5 minutes. The same trend
was observed in the positive control, human ASMCs (purple line) but not in the negative
control HeLa cells (grey line). Freshly dissociated rat aortic SMCs (orange line) served as
the optimal physiological control and demonstrated prolonged increase in intracellular
calcium over the first 3 minutes. The derived SMCs exhibited comparable peak fluorescence
responses to both the cultured and freshly dissociated SMC controls (Fig. 3bii). Time-lapse
microscopy showed that our SMCs and ASMCs contracted in a tonic fashion during the 10
minutes of carbachol treatment (Fig. 3c and Supplementary Videos 1-5), consistent with the
sustained contraction usually manifested by vascular SMCs in controlling vessel tone.
Contracting cells exhibited between 10-20% change of cell surface area (n = 20). Over 50%
and 20% of all derived SMCs contracted upon carbachol and angiotensin II treatments
respectively (Supplementary Fig. 4a,b). PM-SMC demonstrated significantly higher
percentage of contractile cells than other SMC subtypes (P = 0.036 versus NE-SMC in
carbachol; P = 0.027 versus NE-SMC and P = 0.013 versus LM-SMC in angiotensin II).
To determine whether the hPSC-derived SMCs could contribute to vessel formation in vivo,
we implanted Matrigel plugs with our SMCs and HUVECs (ratio 1:2) subcutaneously into
immunodeficient mice for two weeks. Sections were immunostained using human-specific
SMTN and PECAM1 antibodies. Luminal structures comprised of HUVECs (PECAM1+,
green) were observed (Fig. 3d). HPSC-derived SMCs (SMTN+, red) were recruited to peri-
endothelial regions, reminiscent of their biological niche. There was between 30-45% SMC
coverage around the endothelial vessel structures with LM-SMCs displaying lower coverage
levels (31.5 ± 5.1%) than the other two groups (43.1 ± 2.6% NE-SMC and 48.9 ± 3.1 %
PM-SMC). These results confirmed the in vitro derived SMCs were functional.
SMC subtypes recapitulate origin-specific requirement for MKL2 and unique responses to
cytokines
To determine whether our system reliably generated origin-specific SMCs from hPSCs, we
validated our model against reported findings from developmental studies. MKL2 is a
transcriptional co-activator for serum response factor which plays a role in early
embryogenesis27. Previous in vivo studies revealed the unique requirement for Mkl2 during
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SMC differentiation from neural crest but not mesoderm28, 29. We postulated that MKL2
was only essential for NE-SMC specification, and not for LM- or PM-SMC specification.
To confirm this hypothesis, we silenced MKL2 using small interfering RNA (siRNA) in our
intermediate populations (Fig. 4a,b). We then induced SMC differentiation and found that
the MKL2 siRNA-treated cells (black bars) showed a significant decrease in SMC gene
expression in NE-SMC (CNN1, P = 0.0006; MYH11, P = 0.015; SMTN, P = 0.0023)
compared to scrambled siRNA control (white bars) while LM-SMC and PM-SMC were
unaffected (Fig. 4c). Likewise, MKL2 knockdown resulted in a significant decrease in the
percentage of MYH11+/ACTA2+ NE-SMC (55.0 ± 4.8% MKL2 siRNA versus 86.7 ± 2.1%
scrambled control, P = 0.0076, Fig. 4d), but no reduction in SMCs derived from mesoderm
origins.
To ascertain that we had generated origin-specific SMC subtypes, we used cytokines known
to induce unique responses in aortic SMCs of distinct origins. Angiotensin II (Ang II)
promotes medial hyperplasia in the ascending aorta (neuroectoderm derivative) but not the
descending aorta (mesoderm derivative)30. TGF-β1 also encourages greater cell
proliferation in SMCs of neuroectoderm origin compared to those of mesodermal
origin31, 32. Consistent with the previous studies, NE-SMC proliferated in response to Ang
II (1 μM, red lines) and TGF-β1 (5 ng/ml, green lines) over 3 days but LM-SMC and PM-
SMC did not (Fig. 4e). Serum (10%, blue lines), a potent mitogen, induced proliferation in
all the SMC subtypes although to a much lesser extent in PM-SMC. Cell cycle analysis
confirmed that Ang II, TGF-β1 or serum each increased the proportion of NE-SMC in S
(yellow bars) and G2-M (blue bars) phases compared to vehicle control after 24 hours (Fig.
4f). LM-SMC and PM-SMC only showed higher S and G2-M populations upon serum
treatment.
Only NE-SMC proliferated in response to TGF-β1 (Fig. 4e-f). This could be due to TGF-β1
enhancing cell proliferation by autocrine production of TGF-β2 and PDGFA31, 32. We
investigated whether TGF-β1 stimulated greater auto-induction of TGF-β2 and PDGFA in
SMCs of a neuroectoderm origin. Our results show that TGFB2 (P = 0.002) and PDGFA (P
= 0.0015) expression were significantly upregulated only in NE-SMC after 10 hours of
TGF-β1 (5 ng/ml) treatment compared with vehicle control (Fig. 4g). Correspondingly,
elevated TGFB2 and PDGFA protein levels were found in NE-SMC lysates after TGF-β1
treatment (Fig. 4h). Taken together, the data on requirement for MKL2 and their unique
proliferative and secretory responses validate the hypothesis that our different SMC
subtypes are analogous to the distinct lineage-dependent SMC populations documented in
vivo.
SMC subtypes predict origin-dependent MMP and TIMP activation
To investigate a link between SMC developmental origins and susceptibility to vascular
diseases, we treated our SMC subtypes with IL-1β (10 ng/ml), an atherogenic cytokine33.
Rat SMCs isolated from various aortic regions (Supplementary Fig. 5) were tested in
parallel. A panel of MMP and TIMP markers, known to be implicated in human
atherosclerosis and aneurysm formation34, was investigated. We discovered that, broadly,
LM-SMC, NE-SMC and PM-SMC (top panel) modeled similar responses to IL-1β as the rat
aortic SMCs (bottom panel) of corresponding origins – root, arch and thoracic descending
(Fig. 5a). In particular, MMP9 and TIMP1 expression levels were differentially activated in
our SMC subtypes, as were rat SMCs of distinct origins. The induction of Mmp9 relative to
control in the rat SMCs was about a 100-fold greater than that in the hPSC-derived SMCs.
This could be due to species-specific variations or different degrees of SMC maturity which
could reflect the differences in level of activation for certain genes. Western blot confirmed
that the hPSC-derived SMCs (top panel) could predict the differential levels of MMP9 and
TIMP1 proteins in the rat aortic SMCs (bottom panel) after exposure to the same stimulus
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(Fig. 5b). The human SMC subtypes also predicted the differential elastin (left panel) and
collagen (right panel) degradation demonstrated by the rat aortic SMCs (Fig. 5c). In
summary, these results suggest that adult SMCs display heterogenous matrix remodeling
responses due, in part, to their different origins. More importantly, our in vitro derived SMC
subtypes are able to effectively model and predict the properties of their in vivo counterparts
and consequently may have relevance in predicting origin-dependent disease responses.
Discussion
We have developed a chemically defined monolayer system to generate origin-specific
vascular SMCs from hPSCs with high efficiency. The initial induction to the intermediate
lineages – neuroectoderm, lateral plate mesoderm and paraxial mesoderm, is instrumental in
defining our subsequent SMC subtypes. Using developmental insights on the BMP gradient
along the primitive streak, we have established novel conditions for mesoderm specification.
Directed differentiation towards the paraxial mesoderm has not been previously reported.
Moreover, our unpatterned lateral plate mesoderm is the only non-specified tissue described
to date. Other published protocols that also use BMP4, generate specific lateral plate
mesoderm derivatives such as blood or cardiac lineages19, 20, 22. The hPSC-derived SMCs
possess contractile function and participate in blood vessel formation in vivo. Although the
SMC subtypes appear phenotypically and functionally indistinguishable, we provide
evidence that they represent truly origin-specific subtypes. More specifically, we show that
they recapitulate differential requirements for SMC fate commitment and unique biological
responses to cytokines consistent with previous in vivo and ex vivo studies28-32. Uniquely,
our in vitro-derived SMC subtypes could predict differential ECM remodeling responses of
regionally distinct rat aortic SMC populations to IL-1β. Currently, findings that can discern
between SMCs from the lateral plate mesoderm and paraxial mesoderm are limited.
Nevertheless, we find that our PM-SMCs are less prone to serum-stimulated proliferation
and ECM degradation, compared to LM-SMCs and NE-SMCs. Moreover, PM-SMCs also
demonstrate greater proportions of contracting cells in response to vasoconstrictors,
suggesting that PM-SMC may be relatively resistant to phenotypic modulation and retain a
more differentiated phenotype than other SMC subtypes. Gene subsets uniquely upregulated
in each of the SMC subtypes (Supplementary Fig. 3a) reveal previously unknown
differences which may guide further studies on the functional relevance of the PM-SMC
population to vascular pathology.
The diverse embryological origins of vascular SMCs are well recognized2. However, it
remains unclear whether the site-specific presentation of some acquired vascular diseases is
attributable to their intrinsic developmental origins. We have shown that origin-specific
SMCs exhibit differential MMP and TIMP activation in response to IL-1β. MMP activation
is associated with SMC phenotypic modulation35, which precedes aneurysm formation in
experimental models36. Degradation of the vessel wall connective tissues by MMPs is a
major pathological remodeling process in an array of human vascular diseases34. We
hypothesized that the differential proteolytic ability of the medial SMC subtypes could
influence the weakening of the aortic wall to different extents. Consequently, regional
discrepancies in vessel mechanical properties may lead to aortic dissection at the boundaries
where SMCs switch origins (Fig. 6). MMPs also induce SMC migration during atheroma
formation in atherosclerosis37. The most deleterious atherosclerotic lesions occur frequently
in the coronary and carotid arteries, which arise from the lateral plate mesoderm and
neuroectoderm respectively. Accordingly, our results demonstrate that LM-SMC and NE-
SMC are predisposed to MMP activation more than PM-SMC. We propose that hardwired
embryonic programs contribute to disease susceptibility, although recognizing that other
factors such as hemodynamic forces and physical structure of the vessels also play important
roles.
Cheung et al. Page 7
Nat Biotechnol. Author manuscript; available in PMC 2012 August 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
The described differentiation system broadly covers most of the origins of vascular SMCs.
Further patterning of the intermediate lineages, for example, the lateral plate mesoderm into
secondary heart field or pro-epicardial lineage, may mimic more closely the precise origins
of SMCs in the aortic root and coronary artery respectively. Our protocols could potentially
be extended to encompass these intermediate sub-populations in future studies. It is
recognized that a small number of SMC populations may be derived from embryonic tissues
beyond those that we have modeled, for example renal SMCs which are thought to originate
from the metanephric mesenchyme, an intermediate mesoderm derivative, which is not
modeled here. Additionally, it is likely that the hPSC-derived SMCs represent a fetal
phenotype, possibly due to lack of heterotypic cell-cell interactions and in vivo
microenvironment cues. In spite of this, our in vitro SMC differentiation system is the first
to define conditions for generating SMCs from different embryological origins. Elucidating
the molecular mechanisms underlying origin-dependent differences in SMC behavior may
provide clues to understanding how SMC origins influence a variety of vascular disease
patterns.
Furthermore, our ability to produce large amounts of SMC subtypes from hPSCs will be
essential for far-reaching applications in vascular disease modeling and regenerative
medicine. Genetic syndromes38, 39 and hereditary influences40-42 seem to be closely linked
to SMC dysfunction in the thoracic aorta43. Congenital vascular diseases such as cono-
truncal defects44 or patients with CADASIL45 feature mutations that predominantly affect
neural crest-derived SMCs. Disease modeling with the appropriate origin-specific SMCs
generated from patient-derived iPSCs is therefore vital for accurate assessment and
therapeutic discovery. Patient matched SMCs may also be used to construct bio-engineered
blood vessels for coronary and peripheral artery bypass or hemodialysis grafts. Meanwhile,
for optimal outcomes in tissue or whole-organ regeneration, adequate vascularization is
necessary. Hence, to maximize success in both disease modeling and regenerative medicine,
it may be useful to focus on SMCs that are derived from the same embryonic lineage as in
the tissue/organ affected.
Methods
HPSC culture
HESCs (lines H9 and H1 [WiCell, Madison, WI], passages 65-85) were cultured in a
chemically defined medium (CDM) as previously described46. Human iPSCs were obtained
from the Cambridge Biomedical Research Centre iPSC Core Facility (www.cambridge-
brc.org.uk). Briefly, human dermal fibroblasts were isolated from excess skin of patients
undergoing plastic surgery and reprogrammed as previously described47. Human iPSCs
were grown on irradiated mouse feeders and cultured in the typical DMEM/F12 medium,
containing 20% Knockout serum replacement (Gibco) and 4 ng/ml FGF-2 (R&D Systems).
HPSC differentiation
For neuroectoderm differentiation, cells were grown in CDM + SB431542 (10 μM, Tocris)
+ FGF2 (12 ng/ml, R&D systems) for 7 days. For early mesoderm formation, cells were
initially grown in CDM+FGF2 (20 ng/ml, R&D Systems) + LY294002 (10 μM, Sigma) +
BMP4 (10 ng/ml, R&D Systems) for 36 hours. Further specification into lateral plate
mesoderm required CDM+FGF2 (20 ng/ml, R&D Systems) + BMP4 (50 ng/ml, R&D
Systems) for another 3.5 days; whereas paraxial mesoderm required CDM+FGF2 (20 ng/ml,
R&D Systems) + LY294002 (10 μM, Sigma). Upon obtaining the intermediate populations,
cells were trypsinised and cultured in SMC differentiation medium CDM+PDGF-BB (10
ng/ml, PeproTech) + TGF-β1 (2 ng/ml, PeproTech) for at least 12 days. Derived SMCs were
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maintained in CDM deprived of growth factors for at least 24 hours before subsequent
experiments.
Quantitative real-time polymerase chain reaction (QRTPCR)
Total RNA was extracted with RNeasy Mini kit according to the manufacturer’s instructions
(QIAGEN). cDNA was prepared using Maxima First Strand cDNA Synthesis Kit
(Fermentas). QRTPCR mixtures were prepared with SYBR Green PCR Master Mix
(Applied Biosystems). QRTPCR reactions were performed in technical duplicates with the
7500 Fast Real-time PCR System (Applied Biosystems), using the Quantitation –
comparative CT settings. Obtained values were normalized to Porphobilinogen Deaminase
(PBGD). Primer sequences are listed in Supplementary Table 2.
Immunofluorescence and flow cytometry
For immunofluorescence, adherent cells were fixed and permabilized. After blocking with
3% BSA, primary antibody was incubated at 4 °C overnight. Secondary goat anti-mouse
Alexa Fluor 568 and goat anti-rabbit Alexa Fluor 488 antibodies (Invitrogen Molecular
Probes) were used. Finally, nuclei were stained with DAPI. Images were acquired by Zeiss
Axiovert 200M microscope. For flow cytometry, harvested cells were fixed using the
Cytofix/Cytoperm Fixation/Permeabilization kit (BD Biosceinces) and stained according to
the kit manual. Mouse IgG isotype controls (BD PharMingen, 555749, R&D Systems,
IC002C) and non-expressing cell controls (H9 hESCs and HUVECs) were used. Primary
antibodies used for this study are listed in Supplementary Table 3.
Western blot
30 μg of total protein was resolved with SDS-PAGE and transferred to nitrocellulose
membranes. The membrane was probed with primary antibodies (Supplementary Table 3)
and secondary anti-rabbit-HRP (Sigma) and anti-mouse-HRP (Sigma) antibodies. Detection
was performed using the ECL system (GE Healthcare).
Microarray analysis
The Illumina HumanHT-12 v4 BeadArray (http://www.illumina.com/) was used to obtain
global gene expression of hESC and SMC samples. Acquired data was processed with R
statistical programming environment (http://www.r-project.org). Raw and processed data are
available from the ArrayExpress microarray data repository (http://www.ebi.ac.uk/
microarray-as/ae/) under accession numbers E-MTAB-781 (SMC) and E-MTAB-464
(hESC). Heatmaps of relative gene expression were generated with the Heatmap Builder
software48 (downloaded courtesy of the Ashley Lab, Stanford). The statistical over-
representation of functional gene categories (p < 0.01) among genes deemed differentially
expressed between sample group profiles was assessed using the functional annotation
clustering from the DAVID bioinformatics resource49. Refer to Supplementary Methods for
a detailed description of microarray methods.
Cell migration assay
Scratch assay was performed as previously described50.
Contraction study
SMCs were preloaded with the calcium-sensitive fluorophore, Fluo-4 AM (2.5 μM;
Molecular Probes) at 37°C for an hour. Contraction was induced by treating the cells with
carbachol (100 μM, Sigma). Intracellular calcium flux was measured using the FL1 channel
of CyAn ADP flow cytometer (Beckman Coulter). Contraction videos of SMCs were
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acquired by a time-lapse microscope (Olympus IX700) during 10 minutes of carbachol
treatment. Change of cell surface area was assessed by ImageJ software.
Matrigel plug implantation
In vivo studies were compliant with the UK Home Office: Animals In Scientific Procedures
guidelines and approved by the University of Cambridge. Derived SMCs and HUVECs
(ratio 1:2) were resuspended in ice cold matrigel basement membrane matrix (BD
Biosciences) at a final cell concentration of 106 cells/ml. 750 μl of cell suspension was
injected subcutaneously into Rag2-null immunodeficient male mice. After 2 weeks, the
animals were sacrificed and the matrigel plugs were excised to be paraffin embedded. The
sections were then immunostained and imaged with a confocal microscope (Zeiss,
LSM700).
Short interfering RNA (siRNA) gene silencing
Transient knockdown of MKL2 was carried out with ON-TARGETplus SMARTpool
siRNA by DharmaFECT transfection reagent (Thermo Scientific Dharmacon). 10 nM of
siRNA was used for transfection according to the manufacturer’s instructions. Messenger
RNA and protein analyses were performed at 24 hours and 48 hours post-transfection
respectively.
Proliferation assays
For cell proliferation assay, hESC-derived SMCs were seeded 6,000 cells/well into 96-well
plates. Following incubation overnight, TGF-β1 (5 ng/ml, PeproTech), angiotensin II (10
μM, Sigma) or 10% FBS (Sigma) was added. Cell viability was measured as a function of
the metabolic activity using tetrazolium salt, MTT (Sigma). At every timepoint, MTT (0.5
mg/ml) was incubated with the cells at 37°C for 2 hours and then solubilized using DMSO
(Sigma) at 37°C for 15 min. Absorbance was measured at 550 nm using the Wallac Envision
2104 multilabel reader (PerkinElmer). For cell cycle analysis, hESC-derived SMCs were
harvested and the cell suspension was fixed by ice cold 70% ethanol for 30 minutes at 4°C.
To ensure that only DNA is stained, cells were treated with 100 μg/ml of ribonuclease.
Finally, cells were stained with 50 μg/ml of propidium iodide in the dark at room
temperature for 30 minutes. Cell fluorescence was measured by a flow cytometer (Beckman
Coulter CyAn ADP) and cell cycle analysis was performed using FlowJo software.
Rat primary SMC culture
Rats were euthanized using carbon dioxide and different aortic regions were surgically
dissected. Aortic segments were incubated with 12.5 ml of enzyme solution composing of 1
mg/ml collagenase II (Worthington), 1 mg/ml soybean trypsin inhibitor (Worthington), 9.3
units activity elastase (Worthington), 125 μl pen-strep and 12.5 ml HBSS (Gibco) for 20
minutes at 37°C. Adventitia was removed and aortic segments were rinsed to remove intimal
cells. Remaining medial segments were snipped into 0.5-1 mm pieces and enzyme treated
again for 1 hour with occasional agitation. Dissociated SMCs were cultured in DMEM
supplemented with 10% FBS, 100 U/mL of penicillin and 100 mg/mL of streptomycin. Rat
SMCs were serum-starved for at least 24 hours before experimentation. All experiments
were performed with cells during passages 2–4.
Proteolytic assays
96-well plates were coated with either 0.1 mg/ml of elastin or collagen type I, of which both
were FITC conjugated (AnaSpec). HESC-derived SMCs or rat SMCs were then seeded
6,000 cells/well. Following incubation overnight, 10 ng/ml of IL-1β (PeproTech) was added
in serum-free media. Activity of secreted proteases was assessed by the increase of
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fluorescence measured at excitation/emission = 490 nm/ 520 nm using the Wallac Envision
2104 multilabel reader (PerkinElmer). To take into account any differential cell proliferation
due to IL-1β, the fluorescence readout was normalized against the corresponding cell
number/well.
Statistics
Results are presented as mean ± s.e.m. of 3 independent experiments unless otherwise
stated. Statistical P values were calculated by Student’s t-test unless otherwise stated.
Significant differences are indicated as *P< 0.05; +P < 0.01; ^P < 0.001.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Induction of mesoderm subtypes from hPSCs. (a) (i) HPSCs were initially differentiated to
early mesoderm using FGF2, LY294002 and BMP4 (depicted as FLyB) for 36 hours.
Mesoderm subtype specification required another 3.5 days of FGF2+LY294002 (FLy) or
FGF2+BMP4 (FB) for paraxial or lateral plate induction. (ii) BMP concentration gradient
exists along the primitive streak (PS). On the basis of fate map studies, mesoderm subtypes
emerge along the gradient on the embryo cylinder. (b) KDR and MEOX1 expression levels
of hESCs differentiated for 36 hours in FLyB, followed by 3.5 days in FGF2+LY294002
with Noggin (Nog), BMP4 (B) and/or Activin (A) were determined by QRTPCR. BMP4
concentrations ranged from 0 ng/ml (B0) to 100 ng/ml (B100). (c) Lateral plate and paraxial
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mesoderm marker expression levels in hESCs differentiated for 36 hours in FLyB and then
3.5 additional days in FGF2 (F) or FGF2+BMP4 (FB50, where BMP4 is 50 ng/ml), with
(black bars) or without (white bars) LY294002 (Ly) determined by QRTPCR. (d) Temporal
QRTPCR to analyze mesoderm specification. Following a common 36-hour treatment of
FLyB, lateral and paraxial mesoderms were specified using FB50 (red line) and FLy (blue
line) respectively. (e) Percentage of KDR+ and TCF15+ cells at days 3 and 5 determined by
flow cytometry. (f) At day 5, FB50- and FLy-treated populations were immunostained for
mesoderm subtype-specific markers. Scale bars, 100 μm. Data represent means ± s.e.m. (n =
3). Significant differences compared to day 0 population are indicated in black, while that
between two groups are indicated in red (*P < 0.05; +P < 0.01; ^P < 0.001).
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Figure 2.
Efficient differentiation of intermediate lineages into vascular SMCs. (a) A schematic which
outlines the conditions for deriving origin-specific SMCs from hPSCs. FLyB+FB and FLyB
+FLy have been described in Figure 1 to generate the lateral plate mesoderm (LM) and
paraxial mesoderm (PM) respectively. HPSCs were treated with FGF2+SB431542 (FSb) for
7 days to induce neuroectoderm (NE) differentiation. For further differentiation into
vascular SMCs, each intermediate population was subjected to PDGF-BB+TGF-β1 (PT) for
12 additional days. The SMC subtypes, namely the neuroectoderm-derived SMC, lateral
mesoderm-derived SMC, paraxial mesoderm-derived SMC are abbreviated as NE-SMC,
LM-SMC and PM-SMC respectively. (b) QRTPCR demonstrated increasing expression of
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SMC markers during the 12 days of PT treatment on the three intermediate populations.
Data represent means ± s.e.m. (n = 3). (c) Flow cytometric analysis demonstrated that the
SMC differentiation protocols were highly efficient and reproducible in three hPSC lines
with 83-92% of the resulting populations double positive for MYH11 and CNN1. (d)
Microarray gene expression heat map of control hESCs versus SMC subtypes obtained after
12 days of PT treatment. Red (upregulation) and blue (downregulation) depict differential
gene expression from the mean across all samples. (e) The majority of our SMC subtypes
immunostained positively for CNN1 (red) and TAGLN (green). Human umbilical vein
endothelial cell (HUVEC) was used as a negative control, while ASMC was used as a
positive control. Scale bars, 100 μm. (f) Western blot confirmed the presence of the mature
SMC proteins, MYH11 and SMTN, in the hPSC-derived SMCs and ASMC but not
HUVEC.
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Figure 3.
Functional characterization of hPSC-derived SMCs. (a) Based on global gene expression
profiles, the Venn diagram represent subsets of genes that were differentially upregulated in
the SMC subtypes compared to hESC (FDR 0.1%). The commonly upregulated 3,604 genes
were analyzed using the functional annotation clustering from DAVID bioinformatics
resources. Among the top 20 highly enriched groups, functional characteristics pertaining to
vascular SMCs are highlighted in yellow. (b) (i) Change in the relative fluorescence unit (Δ
RFU) of Fluo-4 loaded cells was monitored by flow cytometry over 10 minutes after the
addition of carbachol, an inducer of contraction. (ii) Peak Δ RFU of Fluo-4 intensity in
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response to carbachol in the derived SMCs and the SMC controls (n = 3). (c) HPSC-derived
SMCs and ASMC displayed contractile ability in response to carbachol treatment. There
was a 10-20% change of surface area in contracting cells of all SMCs except HeLa cells (n =
20). (d) Matrigel plugs were harvested 2 weeks after the subcutaneous implantation of
hPSC-derived SMCs and HUVECs (1:2). Histological sections were then double
immunostained with human-specific SMTN and PECAM1 antibodies. SMC investment was
quantified based on the relative length of endothelial luminal structures (green) that had
SMC coverage (red) in 10 different optical fields. Statistical test was performed by ANOVA
(*P < 0.05). Scale bars, 50 μm.
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Figure 4.
MKL2 knockdown and cytokine treatments validate the origin-specific characteristics of
hPSC-derived SMC subtypes. (a) 60-65% knockdown of the MKL2 expression levels in the
intermediate populations (NE, LM and PM) by MKL2 siRNA was verified by QRTPCR. (b)
Western blot analysis confirmed the effects of MKL2 siRNA knockdown on the protein
levels compared to scrambled siRNA controls. (c) SMC gene expression levels after SMC
differentiation of the siRNA-treated intermediate populations were determined by QRTPCR.
(d) Percentage of MYH11+/ACTA2+ SMCs obtained from the siRNA-treated intermediate
populations was determined by flow cytometry. (e) Proliferation responses of the SMC
Cheung et al. Page 20
Nat Biotechnol. Author manuscript; available in PMC 2012 August 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
subtypes were monitored by MTT assay every 24 hours over 3 days of treatment with the
cytokines indicated. (f) Cell cycle analysis of the SMC subtypes after 24 hours of cytokine
treatments. The percentage of cells in different phases of cell cycle was quantified by the
areas under the red peak (G0-G1), the area shaded yellow (S) and under the blue peak (G2-
M) (legend on the right). Black dotted lines divide the growth arrested cells in G0-G1 from
the proliferating cells in S and G2-M of the control groups. (g) Gene expression levels in
control and TGF-β1-treated SMCs were determined by QRTPCR after 10 hours of
treatment. (h) Western blot analysis was performed to confirm the distinct secretory
responses exhibited by TGF-β1-treated SMC subtypes. Data represent means ± s.e.m. (n =
3). Significant differences compared to the scrambled siRNA or vehicle controls are
indicated (*P < 0.05; +P < 0.01, ^P < 0.001).
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Figure 5.
HPSC-derived SMC subtypes predict MMP and TIMP expression and activity in rat aortic
SMCs of corresponding origins. (a) Gene expression levels of MMPs and TIMPs in control
(white bars) and IL-1β-treated SMCs (black bars) were determined by QRTPCR after 6
hours of treatment. Differential activation of MMP9 and TIMP1 expression was observed in
both the hPSC-derived SMCs (top panel) and rat aortic SMCs (bottom panel). (b) Western
blot analysis confirmed the differential amounts of MMP9 and TIMP1 proteins in the IL-1β-
treated SMCs of unique origins. (c) Proteolytic abilities of the SMCs were assessed by
elastase and collagenase assays over 2.5 days. The origin-specific SMCs (top panel)
replicated similar trends of elastin and collagen degradation as the rat aortic SMCs (bottom
panel) in response to IL-1β. Data represent means ± s.e.m. (n = 3). Significant differences
compared to the vehicle controls (*P < 0.05; +P < 0.01; ^P < 0.001).
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Figure 6.
The different embryological origins of aortic SMCs may contribute to the site of aortic
dissection. Aortic SMCs originate from three distinct developmental lineages. The aortic
root is derived from secondary heart field, a lateral plate mesoderm derivative (blue solid
arrow), while the ascending aorta and arch are neural crest derived (red solid arrow). The
descending aortic SMCs originate from paraxial/somitic mesoderm (green solid arrow). In
this study, our in vitro hPSC-derived SMC subtypes predicted the differential MMP and
TIMP activation in aortic SMCs of corresponding origins (dotted arrows) in response to an
inflammatory mediator, IL-1β. We propose that the origin-specific SMCs display
differential proteolytic ability in disease settings, which may result in differential loss of the
structural integrity in different regions along the aortic wall. Such a difference in mechanical
properties may predispose the sites of aortic dissection to occur preferentially at the
boundaries between different SMC lineages (indicated by black jagged bolts).
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